H igh-dose (HD) bolus interleukin-2 (IL-2; Proleukin; Novartis) was approved by the Food and Drug Administration (FDA) for the therapy of metastatic renal cell carcinoma (RCC) in 1992 based on its ability to induce durable responses in a small percentage of patients.
1,2 The efficacy of HD IL-2 has subsequently been confirmed in 2 separate large randomized trials. 3, 4 However, due to the limited efficacy and substantial toxicity associated with HD IL-2 administration, only specialized centers continue to offer this therapy and most efforts have been focused on developing selection strategies to limit IL-2 therapy to those patients most likely to experience benefit. 5, 6 Meanwhile, greater attention has been focused on developing molecularly targeted therapies for RCC based on our growing knowledge of its molecular biology. The majority of sporadic clear cell RCC cases are characterized by somatic bi-allelic alterations in the von Hippel-Lindua gene resulting in inappropriate accumulation of hypoxiainducible factor-1a and hypoxia-inducible factor-2a and subsequent activation of their target genes including vascular endothelial growth factor (VEGF). 7 Accordingly, a new class of agents targeting VEGF signaling has emerged that have demonstrated significant clinical efficacy in patients with advanced RCC. Bevacizumab (Avastin, Genentech), a humanized monoclonal antibody against VEGF, has shown promising activity both as a single agent and in combination with interferon (IFN) a-2b. [8] [9] [10] Similarly, the oral multitargeted tyrosine kinase inhibitors (TKIs), sorafenib and sunitinib, have been approved by the FDA for the therapy of patients with advanced RCC after showing substantial activity in phase II and phase III trials both for treatment-naive and cytokine-refractory patients. [11] [12] [13] [14] Given their efficacy, toxicity profile, and ease of administration, development of these molecularly targeted agents represents a clear breakthrough in the treatment of metastatic RCC.
Not surprisingly, VEGF-targeted agents have been advocated as first-line therapy for patients with advanced RCC. However, it must be noted that responses to these agents are typically neither complete nor durable off therapy and most patients will therefore require secondline therapy. With multiple therapeutic options now available to patients with RCC, the most appropriate sequencing of these therapies must be investigated. During the clinical development of VEGF-targeted therapies, it was assumed that patients receiving these agents could be considered for IL-2 in the second-line or third-line setting. However, both sorafenib and sunitinib have demonstrated efficacy after cytokine therapy (IL-2 or IFN), [11] [12] [13] the safety and efficacy of HD IL-2 after prior therapy with VEGFtargeted agents remains unexplored. Toward this end, we have conducted a retrospective analysis of clinical outcomes of patients treated with HD IL-2 at the Beth Israel Deaconess Medical Center (BIDMC) and Vanderbilt University Medical Center (VUMC) after prior therapy with VEGF-targeted agents.
MATERIALS AND METHODS

Patient Selection
Patients included in this retrospective analysis were consecutive patients assessed for salvage HD IL-2 therapy at the Beth Israel Deaconess Medical Center and Vanderbilt Medical Center between July 2004 and May 2007 after prior treatment with at least 1 VEGF-targeted therapy. All patients had demonstrated disease progression on VEGFtargeted therapy before the consideration of IL-2. VEGFtargeted therapy included bevacizumab, sorafenib, or sunitinib. Patients were required to meet after criteria before IL-2 therapy: an Eastern Collaborative Oncology Group performance status of 0 or 1; adequate organ function, with normal hematologic parameters; serum creatinine r1.5 mg/dL or calculated creatinine clearance of greater than 60 mL/min; forced expiratory volume in 1 second greater than 2.0 L/s or 75% of predicted value; no evidence of congestive heart failure, serious cardiac arrhythmia, symptoms of coronary artery disease, or ischemia on cardiac stress test; no contraindications to the use of pressor agents; no active infection requiring antibiotic therapy; and no medical condition requiring corticosteroids.
IL-2 Therapy
Patients meeting eligibility requirements received HD IL-2 according to standard protocol. IL-2 was given as a bolus 600,000 U/kg/dose intravenously every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15 of a standard 12 weeks cycle. Each weeklong admission was defined as a course. All patients underwent placement of a central venous catheter before each course of therapy and received antibiotic prophylaxis [ciprofloxacin 250 mg orally (PO) twice daily (BID), levofloxacin 500 mg PO daily or cephalexin 500 mg PO BID] on days 1 to 10 and days 15 to 24 of each cycle. All antihypertensive medications were discontinued at least 24 hours before first dose of IL-2. Patients not meeting eligibility requirement for HD IL-2 received low-dose (LD) IL-2 therapy with bolus doses of 60,000 U/kg/dose intravenously on the same schedule as HD IL-2. All patients also received: acetaminophen (650 mg PO every 4 h) and indomethacin (25 mg every 6 h) to reduce febrile reactions; ranitidine (150 mg PO BID) or famotidine (20 mg PO BID) for prophylaxis for gastrointestinal bleeding; hydroxyzine hydrochloride (25 mg to 50 mg PO every 6 h) or diphenhydramine (25 mg PO every 6 h) for pruritis; meperidine (25 mg to 50 mg PO every 6 h) for chills and rigors; an antidiarrheal agent, antiemetics, anxiolytics, diuretics, and vasopressors as needed. Patients were evaluated for response during weeks 6 and 12 of the first cycle. Patients considered for retreatment had to experience objective response [partial response (PR) or complete response (CR)] or at least minor tumor regression and meet all baseline eligibility criteria for organ function.
Dose Modification for IL-2
Treatment with IL-2 was modified by withholding doses rather than continuing therapy at a reduced dose. Doses of IL-2 were withheld for: hypotension refractory to fluids and pressors or requiring unacceptably high pressor doses (dose); anuria for more than 24 hours unresponsive to fluid replacement and LD dopamine; respiratory distress requiring more than 4 L of oxygen to maintain O 2 saturation greater than 95%; confusion, sustained ventricular tachycardia (>130) or any sign or symptoms of myocardial ischemia or myocarditis; metabolic acidosis with HCO 3 less than 18 despite attempts to correct with HCO 3 ; atrial fibrillation, documented systemic infection, or any other serious toxicity that was not controlled at the time of next dose.
Response and Toxicity Assessment
Standard WHO response criteria were used. CR was defined as the complete absence of all clinical evidence of malignant disease for at least 2 determinations 4 weeks apart. PR required a greater than 50% decrease in the sum of the products of the perpendicular diameters of all measurable lesions for at least 2 measurements 4 weeks apart. Stable disease was defined as less than 50% reduction, no change, or less than 25% increase in disease and no new disease. Progressive disease was defined as a greater than 25% increase in the sum of the products of perpendicular diameters of all lesions or the appearance of any new lesion. Toxicity was evaluated using the National Cancer Institute Common Toxicity Criteria version 3.0.
Statistical Methods
In this retrospective analysis, descriptive statistics are presented as number and percentage or as median, interquartile range (IQR; 25th to 75th percentiles) and range (minimum to maximum). Comparisons of proportions between patients who did and did not receive prior TKIs used Fisher exact or Wilcoxon rank-sum tests. Exact methods were used to calculate 2-sided 95% confidence intervals (CIs) and P values.
RESULTS
Patient Characteristics
Twenty-three consecutive patients who received salvage IL-2 between July 2004 and May 2007 at the Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center were analyzed. All patients were considered excellent candidates for HD IL-2 before initiating VEGF-targeted therapy, but received VEGFtargeted agents with the assumption that IL-2 could be safely given at a later date.
Patient characteristics and prior therapies are shown in Table 1 . Patients ranged from 42 to 70 years of age and 19 of 23 patients (83%) were male. Eight patients received bevacizumab as their only VEGF-targeted therapy before IL-2; 3 patients received sorafenib alone; 3 patients received sunitinib alone; 2 patients received both sorafenib and sunitinib; 4 patients received bevacizumab followed by sunitinib; 1 patient received bevacizumab in combination with sorafenib as part of a phase I trial 15 ; 1 patient received bevacizumab followed by sorafenib, and 1 patient received IFN/bevacizumab followed by sorafenib. Eleven of 15 patients treated with bevacizumab received this medication as part of a phase II randomized trial of bevacizumab plus erlotinib versus placebo. 16 One patient received bevacizumab as part of a phase II trial of bevacizumab plus erlotinib plus imatinib. 17 Overall, 15 (65%) of the 23 patients had been treated with a TKI (ie, sorafenib or sunitinib). The median duration of TKI use among the 15 patients was 4 months (IQR, 3 to 7 mo; range, 0.5 to 12 mo).
IL-2 Therapy
The details of IL-2 therapy for patients in this analysis are shown in Table 2 
Response and Toxicity
The clinical response and toxicities observed in patients treated with salvage IL-2 after VEGF-targeted therapy are shown in Table 2 . Only 1 of 23 patients proceeded to receive a second cycle of IL-2. No patients achieved a PR or CR to therapy (95% CI, 0-14.8%); 3 patients experienced stable disease (1, 8, 9 mo in duration), 19 progressive disease, and 1 patient died during the treatment.
The patients who received prior TKI (sunitinb, sorafenib, or both) therapy received fewer total IL-2 doses during cycle 1 than the patients who were pretreated with bevacizumab only (median, 15 vs. 20 doses; P = 0.08 by Wilcoxon rank-sum test). Both groups received similar numbers of doses in week 1 of cycle 1 (median, 12 vs. 11 doses), but the TKI-treated group received fewer doses in week 2 (median, 6 vs. 9 doses,). In total, 6 (40%; 95% CI, 16%-68%) of 15 patients who received prior TKI did not receive week 2 of IL-2 therapy as compared with none of the 8 patients (0%; 95% CI, 0%-37%) who did not receive prior TKI.
Six of 23 (26%, 95% CI, 10.2%-48.4%) patients in this analysis experienced severe (grades III to V) cardiovascular toxicity. These events are detailed in Table 3 . All 6 of 
DISCUSSION
During the clinical development of VEGF-targeted agents in RCC, many patients have received these agents as their initial therapy with the assumption that IL-2 would be a therapeutic option once they experience disease progression. With the recent FDA approval of sorafenib and sunitinib in advanced RCC, the use of VEGF-targeted therapy has been expanding rapidly in the community. As patients previously treated with these agents will likely compose an ever-increasing proportion of the referrals to specialized IL-2 treatment centers, we conducted this retrospective analysis to explore the safety and efficacy of IL-2 after failure of VEGF-targeted therapy.
Our analysis suggests that the toxicity of IL-2 therapy may be higher in patients who have received prior VEGFtargeted therapy. Interestingly, this increased toxicity seems to specifically be limited to those patients who had received prior TKI compared with bevacizumab alone. Patients who received prior TKI received fewer doses on average in cycle 1 compared with those who had not (median, 15 vs. 20) and had a markedly high rate of severe cardiovascular toxicity (40%). All 6 severe cardiovascular events were in patients who had prior TKI compared with none in patients who had only received bevacizumab. Although the small size and retrospective nature of this analysis makes a direct statistical comparison inappropriate, as a point of reference, the rate of severe grade (III to V) cardiovascularity reported in the HD IL-2 arm of the recent phase III Cytokine Working Group (CWG) trial in metastatic RCC was 8.5%. 4 Potential etiologies for the observed incidence of cardiovascular events remain speculative. The distinction between bevacizumab and TKIs with regard to the incidence of cardiovascular events is perhaps not surprising as the TKIs have many other effects besides inhibition of VEGF signaling. Both sorafenib and sunitinib would be expected to alter multiple intracellular signaling pathways not just in the tumor but also in normal vasculature and also in other organs, such as the heart. Sunitinib has been demonstrated to reduce cardiac ejection fraction by at least 10% in 28% of patients treated at the approved dose. 18 In animal models, the mechanism of this decline in left ventricular function was felt to be direct cardiomyocyte toxicity through mitochondrial injury. Perhaps more concerning are reports that have suggested that the cardiotoxicity induced by sunitinib may not be completely reversible once therapy has been discontinued. These reports have suggested that intact signaling through tyrosine kinase receptors, particularly that through PDGFR, is critical to myocardial remodeling and survival in response to stress. 19, 20 It is therefore not surprising that sorafenib, which inhibits many of the same tyrosine kinases as sunitinib, may also have cardiotoxic effects in patients who have received prior sunitinib. 21 Finally, both sorafenib and sunitinib very commonly induce hypertension, possibly exacerbating the myocardial toxicity of these agents by inducing the very cardiovascular stress to which myocytes can no longer appropriately respond due to pharmacologic inhibition of tyrosine kinase receptor-mediated signaling.
Although all patients who received HD IL-2 in this analysis were required to show no evidence of clinical congestive heart failure or active ischemia on cardiac stress test before receiving therapy, echocardiograms were not routinely performed as part of the screening evaluation. Patients with prior TKI exposure may also have subclinical myocardial or endothelial injury unapparent during screening but unmasked by HD IL-2 therapy during which patients are frequently hypotensive, tachycardic, on vasopressive agents, and have high levels of circulating tumor necrosis factor. More intense cardiac screening tests may be needed in this group of patients before considering HD IL-2 therapy.
Although this study may not have had adequate numbers to detect a relationship between cardiovascular toxicity and the duration of time from the cessation of a TKI and initiation of HD IL-2 therapy, this remains a potential concern. The 1 patient who experienced a sudden cardiac arrest had stopped sunitinib only 10 days before starting HD IL-2. It has been shown that some of the deleterious cardiovascular complications of sunitinib resolve off therapy, 18 suggesting that patients with prior exposure should perhaps be observed longer than usual after TKI cessation before considering HD IL-2.
In this analysis, no patient treated with IL-2 after VEGF-targeted therapy experienced a PR or CR. Although the historical response rates for IL-2 are typically in the 15% to 20% range, 1,2 the clinical significance of the lack of responses observed in this study is unclear as the efficacy of HD IL-2 in the salvage setting is not well characterized. The median number of doses received by patients in this analysis during cycle 1 (19 doses) is actually equal to that reported in the CWG trial, 4 suggesting that the observed lack of efficacy cannot completely be attributed to receiving fewer doses of IL-2. Patients who received prior TKI did tend to receive fewer doses in cycle 1 compared with those who had not received prior TKI (median, 15 vs. 20 doses; P = 0.08), possibly contributing the lack of efficacy in this subset of patients.
It is perhaps not surprising that IL-2 may have less efficacy in heavily pretreated patients as RCC has been shown to induce host immune suppression through a variety of mechanisms including MHC class I-mediated suppression of NK-cell activity, downregulation of TCRz chain expression, upregulation of expression of B7-H1 expression by RCC, inhibition of dendritic cell function, and upregulation of regulatory T cells (Tregs) and myeloid suppressor cells. [22] [23] [24] [25] As these effects may increase over time due to increasing tumor bulk, none of these effects may be specific to prior therapy with VEGF-targeted agents. Although it is becoming increasingly clear that VEGFtargeted agents may have immunomodulatory properties, [26] [27] [28] the fact that the median time from prior VEGFtargeted therapy cessation to IL-2 therapy was 2 months makes a contribution of such properties to the observed findings unknown. Regardless, potential etiologies for the lack of efficacy of IL-2 in this small group of patients are purely speculative and this result must be confirmed through larger analysis.
Although our sample size is small, this retrospective analysis raises several potential concerns regarding IL-2 therapy after prior VEGF-targeted therapy. Although these findings must be validated through larger analyses, they suggest potential alterations in the approach of delivering IL-2 in this group of patients. The incidence of cardiovascular events in patients treated with prior TKI and the reported cardiovascular complications of these drugs themselves suggest that these patients should be subjected to more rigorous cardiovascular screening before initiation of IL-2. This screening process could include an evaluation of left ventricular function by echocardiogram or RVG and nuclear cardiac stress testing in addition to the standard screening studies. The potential reversibility of the cardiovascular side effects of TKI off drug suggests that patients should be off TKIs at least 1 to 2 months before initiation of IL-2. Finally, although there are now several therapeutic options for patients with advanced RCC, IL-2 remains the only therapy that has been shown to potentially induce durable remissions off therapy. The reduced efficacy and enhanced toxicity observed in heavily pretreated patients argues that IL-2 should be considered as a primary therapy for those patients who have been appropriately selected according to increasingly more robust selection strategies.
